Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

This phase II trial studies how well naive T-cell depletion works in preventing chronic graft-versus-host disease in children and young adults with blood cancers undergoing donor stem cell transplant. Sometimes the transplanted white blood cells from a donor attack the body's normal tissues (called graft versus host disease). Removing a particular type of T cell (naive T cells) from the donor cells before the transplant may stop this from happening.

Trial Details

NCT ID
NCT03779854
Phase
PHASE2
Sponsor
Fred Hutchinson Cancer Center
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • Total-Body Irradiation
  • Thiotepa
  • Fludarabine
  • Cyclophosphamide
  • Busulfan
  • Allogeneic Bone Marrow Transplantation
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Iowa City, Iowa, United States|41.66113,-91.53017
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • The patient must have one of the following diagnoses and be considered to be an appropriate candidate for allogeneic HCT by the study site principa…
  • Acute lymphoblastic leukemia (ALL) with \< 5% marrow blasts.
  • Acute myeloid leukemia (AML) with \< 25% marrow blasts.
  • Other acute leukemia (OAL) or related neoplasm (including but not limited to acute biphenotypic leukemia \[ABL\], ambiguous lineage \[ALAL\], mixed…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →